Stocks of Conmed Corp (NYSE:CNMD) traded higher last session on Wall Street, up 1.24% to $67.69.
CNMD stock price is now -5.51% away from the 50-day moving average and -4.43% away from the 200-day moving average. The market capitalization of the company currently stands at $2.09B.
With the price target enhanced from $119 to $129, Needham maintained Buy rating for Conmed Corp (NYSE: CNMD). On May 22, 2023, CL King recently initiated its ‘Buy’ rating on the stock quoting a target price of $140, while ‘KeyBanc Capital Markets’ rates the stock as ‘Overweight’
In other news, Hartman Curt R, Officer bought 2,849 shares of the company’s stock on Nov 08 ’24. The stock was bought for $213,219 at an average price of $74.84. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 27 ’24, Officer Peters Stanley W III bought 2,171 shares of the business’s stock. A total of $157,181 was incurred on buying the stock at an average price of $72.40. A total of 2.78% of the company’s stock is owned by insiders.
During the past 12 months, Conmed Corp has had a low of $61.05 and a high of $110.75. As of last week, the company has a debt-to-equity ratio of 1.01, a current ratio of 2.27, and a quick ratio of 1.06. According to the stock market information, the enterprise value for the company is $2993345792, which is based on a 16.05 price-to-earnings ratio, a 0.99 price-to-earnings-growth ratio, and a beta of 1.47. The fifty day moving average price for CNMD is $71.6362 and a two-hundred day moving average price translates $70.8245 for the stock.
The latest earnings results from Conmed Corp (NYSE: CNMD) was released for 2024-09-30. The net profit margin was 10.25% and return on equity was 15.24% for CNMD. The company reported revenue of $316.7 million for the quarter, compared to $304.58 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 3.98 percent. For the current quarter, analysts expect CNMD to generate $341.03M in revenue.
